Activated T cells and cytokine-induced CD3+CD56+ killer cells |
| |
| Authors: | G. D. Schmidt-Wolf R. S. Negrin I. G. H. Schmidt-Wolf |
| |
| Affiliation: | (1) Department of Medicine, Division of Hematology/Oncology, Virchow Clinic of Humboldt University, Augustenburger Platz 1, D-13353 Berlin, Germany, DE;(2) Bone Marrow Transplantation Program, Stanford University Medical Center, Stanford, CA, USA, US |
| |
| Abstract: | ![]()
Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells may be suitable to remove residual tumor cells. Received: 7 October 1996 / Accepted: 13 November 1996 |
| |
| Keywords: | T cells Cytokine-induced killer cells Immunotherapy |
| 本文献已被 SpringerLink 等数据库收录！ |
|
